This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hrushesky, W. J. Articles by Cope, F. O. Search for Related Content PubMed PubMed Citation Articles by Hrushesky, W. J. Articles by Cope, F. O.

Circulation, Vol 84, 697-707, Copyright © 1991 by American Heart Association

ARTICLES

Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin- induced cardiomyopathy

WJ Hrushesky, DJ Fader, JS Berestka, M Sommer, J Hayes and FO Cope
Department of Medicine (Medical Oncology), Albany Medical College, NY.

BACKGROUND. The development of a microcomputer-based device permits quick, simple, and noninvasive quantification of the respiratory sinus arrhythmia (RSA) during quiet breathing. METHODS AND RESULTS. We prospectively and serially measured the radionuclide left ventricular ejection fraction and the RSA amplitude in 34 cancer patients receiving up to nine monthly bolus treatments with doxorubicin hydrochloride (60 mg/m2). Of the eight patients who ultimately developed symptomatic doxorubicin-induced congestive heart failure, seven (87.5%) demonstrated a significant decline in RSA amplitude; five of 26 subjects without clinical symptoms of cardiotoxicity (19.2%) showed a similar RSA amplitude decline. On average, significant RSA amplitude decline occurred 3 months before the last planned doxorubicin dose in patients destined to develop clinical congestive heart failure. CONCLUSION. Overall, RSA amplitude abnormality proved to be a more specific predictor of clinically significant congestive heart failure than did serial resting radionuclide ejection fractions.

This article has been cited by other articles:

				J. J. Doyle, A. I. Neugut, J. S. Jacobson, V. R. Grann, and D. L. Hershman Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study J. Clin. Oncol., December 1, 2005; 23(34): 8597 - 8605. [Abstract] [Full Text] [PDF]

				H. Tsuji, M. G. Larson, F. J. Venditti, E. S. Manders, J. C. Evans, C. L. Feldman, and D. Levy Impact of Reduced Heart Rate Variability on Risk for Cardiac Events: The Framingham Heart Study Circulation, December 1, 1996; 94(11): 2850 - 2855. [Abstract] [Full Text]

				J. H. Silber, G. Barber, L. Paz-Ares, N. Dobbs, and C. Twelves Doxorubicin-Induced Cardiotoxicity N. Engl. J. Med., November 16, 1995; 333(20): 1359 - 1360. [Full Text]

				S. E. Lipshultz, S. R. Lipsitz, S. M. Mone, A. M. Goorin, S. E. Sallan, S. P. Sanders, E. J. Orav, R. D. Gelber, and S. D. Colan Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer N. Engl. J. Med., June 29, 1995; 332(26): 1738 - 1744. [Abstract] [Full Text] [PDF]